Cronos Group reports Q3 EPS 7c vs 2c last year

Reports Q3 revenue $36.339M vs $34.264M last year. “Our third quarter results reflect continued progress towards our objectives, with the business reaching record levels of net revenue, gross profit and adjusted EBITDA generation, driven by the seventh consecutive quarter of record net revenue at Cronos Israel, as well as by continued cost discipline. Our strength abroad continues to drive robust gross margins, demonstrating the success of our global strategy. Our PEACE NATURALS(R) brand remains the market leader in Israel, supported by outstanding execution from our team on the ground and the consistent success of flagship flower strains, underscoring our ability to scale and innovate efficiently, and to meet the growing needs of patients,” said Mike Gorenstein, Chairman, President and CEO of Cronos.